SNAP-CAR T cells

SNAP-CAR T cells are a universal, programmable chimeric antigen receptor (CAR) T-cell therapy platform designed to overcome the limitations of conventional single-antigen-targeting CAR-T therapies. Developed by researchers at the University of Pittsburgh and licensed to Coeptis Therapeutics, the platform utilizes T cells engineered with a universal receptor containing an extracellular self-labeling SNAP-tag enzyme (a modified O6-alkylguanine-DNA alkyltransferase). Instead of directly binding to tumor antigens, these SNAP-CAR T cells are co-administered with tumor-targeting antibody adaptors (such as monoclonal antibodies) conjugated to a benzylguanine (BG) tag. Upon administration, the BG-tagged antibodies form a highly stable, covalent bio-orthogonal bond with the SNAP-tag on the CAR-T cells, effectively fusing the targeting antibody to the T cell. This modular design allows for tunable dosing to control toxicity, simultaneous or sequential targeting of multiple tumor antigens (such as HER2, CD20, and EGFR) to prevent antigen-escape relapse, and applicability across various hematological and solid tumor malignancies.

Other names

SNAP-CARSNAP-CAR TSNAP-CAR T-cell therapySNAP-CAR T-cellsSNAPpy CAR-T cells